RU2013140625A - Антитела против ангиопоэтина-2 человека - Google Patents
Антитела против ангиопоэтина-2 человека Download PDFInfo
- Publication number
- RU2013140625A RU2013140625A RU2013140625/10A RU2013140625A RU2013140625A RU 2013140625 A RU2013140625 A RU 2013140625A RU 2013140625/10 A RU2013140625/10 A RU 2013140625/10A RU 2013140625 A RU2013140625 A RU 2013140625A RU 2013140625 A RU2013140625 A RU 2013140625A
- Authority
- RU
- Russia
- Prior art keywords
- antibody
- seq
- sequence
- variable domain
- fragment according
- Prior art date
Links
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims abstract 14
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims abstract 14
- 239000003814 drug Substances 0.000 claims abstract 6
- 238000004519 manufacturing process Methods 0.000 claims abstract 6
- 102000009075 Angiopoietin-2 Human genes 0.000 claims abstract 5
- 108010048036 Angiopoietin-2 Proteins 0.000 claims abstract 5
- 150000007523 nucleic acids Chemical class 0.000 claims abstract 3
- 102000039446 nucleic acids Human genes 0.000 claims abstract 3
- 108020004707 nucleic acids Proteins 0.000 claims abstract 3
- 102000009088 Angiopoietin-1 Human genes 0.000 claims abstract 2
- 108010048154 Angiopoietin-1 Proteins 0.000 claims abstract 2
- 101000924552 Homo sapiens Angiopoietin-1 Proteins 0.000 claims abstract 2
- 101000924533 Homo sapiens Angiopoietin-2 Proteins 0.000 claims abstract 2
- 206010027476 Metastases Diseases 0.000 claims abstract 2
- 206010028980 Neoplasm Diseases 0.000 claims abstract 2
- 201000011510 cancer Diseases 0.000 claims abstract 2
- 239000013604 expression vector Substances 0.000 claims abstract 2
- 239000012634 fragment Substances 0.000 claims abstract 2
- 102000044072 human ANGPT1 Human genes 0.000 claims abstract 2
- 102000047825 human ANGPT2 Human genes 0.000 claims abstract 2
- 230000009401 metastasis Effects 0.000 claims abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 2
- 230000002265 prevention Effects 0.000 claims abstract 2
- 208000019553 vascular disease Diseases 0.000 claims abstract 2
- 239000013598 vector Substances 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Ophthalmology & Optometry (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Peptides Or Proteins (AREA)
Abstract
1. Антитело или фрагмент антитела, специфически связывающиеся с ангиопоэтином-2 человека (ANG-2), гдеа) вариабельный домен тяжелой цепи включает область CDR3 с последовательностью SEQ ID NO: 33, область CDR2 с последовательностью SEQ ID NO: 34 и область CDR1 с последовательностью SEQ ID NO: 35 иб) вариабельный домен легкой цепи включает область CDR3 с последовательностью SEQ ID NO: 36, область CDR2 с последовательностью SEQ ID NO: 37 и область CDR1 с последовательностью SEQ ID NO: 38.2. Антитело или фрагмент антитела по п.1, отличающиеся включениема) вариабельного домена тяжелой цепи с последовательностью SEQ ID NO: 39 иб) вариабельного домена легкой цепи с последовательностью SEQ ID NO: 40.3. Антитело или фрагмент антитела по любому из пп.1 или 2, где антитело не связывается с ангиопоэтином-1 человека (ANG-1).4. Антитело или фрагмент антитела по п.1, где указанное антитело является антителом подкласса IgG4 человека или антителом подкласса IgG1 человека.5. Фармацевтическая композиция, отличающаяся включением антитела или фрагмента по пп.1-3.6. Применение антитела или фрагмента антитела по пп.1-3 для получения лекарственного средства для предупреждения метастазирования.7. Применение антитела или фрагмента антитела по пп.1-3 для получения лекарсвенного средства для лечения рака.8. Применение антитела или фрагмента антитела по пп.1-3 для получения лекарсвенного средства для лечения сосудистых заболеваний.9. Нуклеиновая кислота, кодирующая тяжелую цепь антитела, специфически связывающегося с антиопоэтином 2 человека (ANG-2), отличающаяся тем, что указанное антитело включает вариабельный домен тяжелой цепи и вариабельный домен легкой цепи по п.1.10. Вектор экспрессии, отличающийся тем, что вклю�
Claims (11)
1. Антитело или фрагмент антитела, специфически связывающиеся с ангиопоэтином-2 человека (ANG-2), где
а) вариабельный домен тяжелой цепи включает область CDR3 с последовательностью SEQ ID NO: 33, область CDR2 с последовательностью SEQ ID NO: 34 и область CDR1 с последовательностью SEQ ID NO: 35 и
б) вариабельный домен легкой цепи включает область CDR3 с последовательностью SEQ ID NO: 36, область CDR2 с последовательностью SEQ ID NO: 37 и область CDR1 с последовательностью SEQ ID NO: 38.
2. Антитело или фрагмент антитела по п.1, отличающиеся включением
а) вариабельного домена тяжелой цепи с последовательностью SEQ ID NO: 39 и
б) вариабельного домена легкой цепи с последовательностью SEQ ID NO: 40.
3. Антитело или фрагмент антитела по любому из пп.1 или 2, где антитело не связывается с ангиопоэтином-1 человека (ANG-1).
4. Антитело или фрагмент антитела по п.1, где указанное антитело является антителом подкласса IgG4 человека или антителом подкласса IgG1 человека.
5. Фармацевтическая композиция, отличающаяся включением антитела или фрагмента по пп.1-3.
6. Применение антитела или фрагмента антитела по пп.1-3 для получения лекарственного средства для предупреждения метастазирования.
7. Применение антитела или фрагмента антитела по пп.1-3 для получения лекарсвенного средства для лечения рака.
8. Применение антитела или фрагмента антитела по пп.1-3 для получения лекарсвенного средства для лечения сосудистых заболеваний.
9. Нуклеиновая кислота, кодирующая тяжелую цепь антитела, специфически связывающегося с антиопоэтином 2 человека (ANG-2), отличающаяся тем, что указанное антитело включает вариабельный домен тяжелой цепи и вариабельный домен легкой цепи по п.1.
10. Вектор экспрессии, отличающийся тем, что включает нуклеиновую кислоту по п.9 для экспрессии антитела, специфически связывающегося с антиопоэтином 2 человека (ANG-2) в прокариотических или эукариотических клетках-хозяева.
11. Прокариотические или эукариотические клетки-хозяева, включающие вектор по п.10.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08021835 | 2008-12-16 | ||
| EP08021835.7 | 2008-12-16 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2011129204/10A Division RU2569107C2 (ru) | 2008-12-16 | 2009-12-14 | Антитела против ангиопоэтина-2 человека |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2013140625A true RU2013140625A (ru) | 2015-03-10 |
| RU2569461C2 RU2569461C2 (ru) | 2015-11-27 |
Family
ID=40585738
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2011129204/10A RU2569107C2 (ru) | 2008-12-16 | 2009-12-14 | Антитела против ангиопоэтина-2 человека |
| RU2013140625/10A RU2569461C2 (ru) | 2008-12-16 | 2009-12-14 | Антитела против ангиопоэтина-2 человека |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2011129204/10A RU2569107C2 (ru) | 2008-12-16 | 2009-12-14 | Антитела против ангиопоэтина-2 человека |
Country Status (34)
| Country | Link |
|---|---|
| US (12) | US8133979B2 (ru) |
| EP (1) | EP2379592B1 (ru) |
| JP (2) | JP5559191B2 (ru) |
| KR (2) | KR101445518B1 (ru) |
| CN (3) | CN103739709B (ru) |
| AR (2) | AR074756A1 (ru) |
| AU (1) | AU2009328613B2 (ru) |
| BR (2) | BRPI0923434A2 (ru) |
| CA (2) | CA2916481C (ru) |
| CL (2) | CL2011001285A1 (ru) |
| CR (2) | CR20110321A (ru) |
| CY (1) | CY1116264T1 (ru) |
| DK (1) | DK2379592T3 (ru) |
| EC (2) | ECSP11011139A (ru) |
| ES (1) | ES2534635T3 (ru) |
| HK (2) | HK1172349A1 (ru) |
| HR (1) | HRP20150439T1 (ru) |
| HU (1) | HUE024545T2 (ru) |
| IL (2) | IL213039A (ru) |
| MA (1) | MA32876B1 (ru) |
| MX (1) | MX2011005908A (ru) |
| MY (2) | MY155654A (ru) |
| NZ (2) | NZ600005A (ru) |
| PE (2) | PE20140814A1 (ru) |
| PH (1) | PH12013502192A1 (ru) |
| PL (1) | PL2379592T3 (ru) |
| PT (1) | PT2379592E (ru) |
| RU (2) | RU2569107C2 (ru) |
| SG (1) | SG172216A1 (ru) |
| SI (1) | SI2379592T1 (ru) |
| TW (2) | TWI396549B (ru) |
| UA (2) | UA105151C2 (ru) |
| WO (1) | WO2010069532A1 (ru) |
| ZA (2) | ZA201103990B (ru) |
Families Citing this family (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8454960B2 (en) | 2008-01-03 | 2013-06-04 | The Scripps Research Institute | Multispecific antibody targeting and multivalency through modular recognition domains |
| US20110189206A1 (en) | 2008-01-03 | 2011-08-04 | Barbas Iii Carlos F | Antibody Targeting Through a Modular Recognition Domain |
| US8557242B2 (en) | 2008-01-03 | 2013-10-15 | The Scripps Research Institute | ERBB2 antibodies comprising modular recognition domains |
| US8557243B2 (en) | 2008-01-03 | 2013-10-15 | The Scripps Research Institute | EFGR antibodies comprising modular recognition domains |
| US8574577B2 (en) | 2008-01-03 | 2013-11-05 | The Scripps Research Institute | VEGF antibodies comprising modular recognition domains |
| US8268314B2 (en) | 2008-10-08 | 2012-09-18 | Hoffmann-La Roche Inc. | Bispecific anti-VEGF/anti-ANG-2 antibodies |
| US8133979B2 (en) * | 2008-12-16 | 2012-03-13 | Hoffmann-La Roche Inc. | Antibodies against human angiopoietin 2 |
| WO2010112193A1 (en) | 2009-04-02 | 2010-10-07 | Roche Glycart Ag | Multispecific antibodies comprising full length antibodies and single chain fab fragments |
| US20120189635A1 (en) | 2009-07-29 | 2012-07-26 | Regeneron Pharmaceuticals, Inc. | Methods for Treating or Preventing Malaria by Administering an Antibody that Specifically Binds Angiopoietin-2 (Ang-2) |
| JO3182B1 (ar) | 2009-07-29 | 2018-03-08 | Regeneron Pharma | مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2 |
| US8980268B2 (en) | 2009-07-29 | 2015-03-17 | Regeneron Pharamceuticals, Inc. | Methods for treating cancer by administering an anti-Ang-2 antibody |
| SG179196A1 (en) | 2009-09-16 | 2012-04-27 | Genentech Inc | Coiled coil and/or tether containing protein complexes and uses thereof |
| TW201138821A (en) * | 2010-03-26 | 2011-11-16 | Roche Glycart Ag | Bispecific antibodies |
| WO2012009705A1 (en) | 2010-07-15 | 2012-01-19 | Zyngenia, Inc. | Ang-2 binding complexes and uses thereof |
| JP5758004B2 (ja) | 2010-08-24 | 2015-08-05 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | ジスルフィドによって安定化されたＦｖ断片を含む二重特異性抗体 |
| WO2012085111A1 (en) | 2010-12-23 | 2012-06-28 | F. Hoffmann-La Roche Ag | Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery |
| CN102221615A (zh) * | 2011-03-31 | 2011-10-19 | 广州华灿医药科技有限公司 | 一种基于Angiogenin检测的双抗夹心ELISA方法 |
| US9527925B2 (en) | 2011-04-01 | 2016-12-27 | Boehringer Ingelheim International Gmbh | Bispecific binding molecules binding to VEGF and ANG2 |
| US9512220B2 (en) | 2011-04-05 | 2016-12-06 | Neopharm Co., Ltd. | Antibodies against angiopoietins 1 and 2, and their use |
| CN106432506A (zh) | 2011-05-24 | 2017-02-22 | 泽恩格尼亚股份有限公司 | 多价和单价多特异性复合物及其用途 |
| KR102225422B1 (ko) | 2011-09-30 | 2021-03-08 | 다나-파버 캔서 인스티튜트 인크. | 치료 펩티드 |
| MX2014009565A (es) | 2012-02-10 | 2014-11-10 | Genentech Inc | Anticuerpos monocatenarios y otros heteromultimeros. |
| RU2014149681A (ru) * | 2012-05-24 | 2016-07-20 | Ф. Хоффманн-Ля Рош Аг | Антитела с множественной специфичностью |
| BR112014032193A2 (pt) | 2012-06-27 | 2017-06-27 | Hoffmann La Roche | métodos de produção de anticorpos biespecíficos e de determinação de combinação, anticorpo biespecífico, formulação e uso de anticorpo biespecífico |
| WO2014001325A1 (en) | 2012-06-27 | 2014-01-03 | F. Hoffmann-La Roche Ag | Method for making antibody fc-region conjugates comprising at least one binding entity that specifically binds to a target and uses thereof |
| EP3495387B1 (en) | 2012-07-13 | 2021-09-01 | Roche Glycart AG | Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases |
| KR101967345B1 (ko) | 2012-10-18 | 2019-04-09 | 삼성전자주식회사 | 안지오포이에틴-2와 인테그린 간의 결합을 저해하는 펩타이드 및 그 용도 |
| WO2014108854A1 (en) * | 2013-01-09 | 2014-07-17 | Fusimab Ltd. | Monospecific anti-hgf and anti-ang2 antibodies and bispecific anti-hgf/anti-ang2 antibodies |
| EP3666886A1 (en) | 2013-03-15 | 2020-06-17 | Dana-Farber Cancer Institute, Inc. | Therapeutic peptides |
| AU2014236867A1 (en) | 2013-03-15 | 2015-09-24 | Amgen Inc. | Methods and compositions relating to anti-CCR7 antigen binding proteins |
| EP2968541A4 (en) | 2013-03-15 | 2017-02-08 | Zyngenia, Inc. | Multivalent and monovalent multispecific complexes and their uses |
| KR102131371B1 (ko) | 2013-07-02 | 2020-07-08 | 삼성전자주식회사 | Ang-2 특이적 항체 및 그의 용도 |
| EP3381940B1 (en) | 2013-07-29 | 2022-09-07 | Samsung Electronics Co., Ltd. | Anti-ang2 antibody |
| KR102146845B1 (ko) | 2013-07-30 | 2020-08-21 | 삼성전자주식회사 | 앤지오포이에틴-2에 특이적으로 결합하는 항체 및 그의 용도 |
| KR102196450B1 (ko) | 2013-09-17 | 2020-12-30 | 삼성전자주식회사 | Tie2와 결합을 유도하는 항 Ang2 항체를 포함하는 항암제 |
| WO2015091655A1 (en) * | 2013-12-20 | 2015-06-25 | F. Hoffmann-La Roche Ag | Combination therapy with an anti-ang2 antibody and a cd40 agonist |
| KR102206029B1 (ko) | 2014-01-27 | 2021-01-20 | 삼성전자주식회사 | Ang-2에 특이적으로 결합하는 항체 및 그의 용도 |
| JP2017510631A (ja) | 2014-03-14 | 2017-04-13 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | 癌に対しｎｋｇ２ｄ経路機能を回復させるためのワクチン組成物および方法 |
| US9957333B2 (en) * | 2014-04-17 | 2018-05-01 | Case Western Reserve University | Anti-CEP antibody or fragment thereof |
| AR100270A1 (es) * | 2014-05-19 | 2016-09-21 | Lilly Co Eli | Anticuerpos ang2 |
| KR102349370B1 (ko) | 2014-05-26 | 2022-01-10 | 삼성전자주식회사 | 인간화 또는 친화도 성숙된 항 앤지오포이에틴-2 항체 및 그의 용도 |
| CA2963091A1 (en) | 2014-10-06 | 2016-04-14 | Dana-Farber Cancer Institute, Inc. | Angiopoietin-2 biomarkers predictive of anti-immune checkpoint response |
| WO2016061551A1 (en) * | 2014-10-17 | 2016-04-21 | Amgen Inc. | Antibodies directed to angiopoietin-1 and angiopoietin-2 for ocular therapies |
| CA2963606A1 (en) * | 2014-11-10 | 2016-05-19 | F.Hoffmann-La Roche Ag | Anti-ang2 antibodies and methods of use |
| JP6721590B2 (ja) | 2014-12-03 | 2020-07-15 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 多重特異性抗体 |
| EP3250586B1 (en) * | 2015-01-28 | 2021-10-27 | Pieris Pharmaceuticals GmbH | Novel proteins specific for angiogenesis |
| JP6901400B2 (ja) | 2015-04-03 | 2021-07-14 | ゾーマ テクノロジー リミテッド | ＴＧＦ−β及びＰＤ−１の阻害物質を使用する癌の治療法 |
| EP3334762A1 (en) | 2015-08-14 | 2018-06-20 | Allergan, Inc. | Heavy chain only antibodies to pdgf |
| WO2017053807A2 (en) | 2015-09-23 | 2017-03-30 | Genentech, Inc. | Optimized variants of anti-vegf antibodies |
| US10703810B2 (en) | 2015-11-30 | 2020-07-07 | Pieris Australia Pty Ltd. | Fusion polypeptides which bind vascular endothelial growth factor a (VEGF-A) and angiopoietin-2 (Ang-2) |
| WO2018114728A1 (en) | 2016-12-20 | 2018-06-28 | F. Hoffmann-La Roche Ag | Combination therapy with a bispecific anti-ang2/vegf antibody and a bispecific anti-her2 antibody |
| KR102143132B1 (ko) * | 2016-12-26 | 2020-08-10 | 기초과학연구원 | 항 Ang2 항체를 포함하는 안구질환 예방 및 치료용 조성물 |
| WO2018175788A1 (en) | 2017-03-22 | 2018-09-27 | Genentech, Inc. | Hydrogel cross-linked hyaluronic acid prodrug compositions and methods |
| AR111249A1 (es) | 2017-03-22 | 2019-06-19 | Genentech Inc | Composiciones de anticuerpo optimizadas para el tratamiento de trastornos oculares |
| JOP20190245A1 (ar) | 2017-04-20 | 2019-10-15 | Novartis Ag | أنظمة توصيل إطلاق مستدام تتضمن روابط بلا أثر لنقطة الربط |
| WO2019164219A1 (en) * | 2018-02-20 | 2019-08-29 | Institute For Basic Science | Anti-angiopoietin-2 antibodies and uses thereof |
| KR102497171B1 (ko) | 2018-02-20 | 2023-02-08 | 기초과학연구원 | 항-안지오포이에틴-2(Ang2) 항체 및 그의 용도 |
| AR116566A1 (es) | 2018-10-03 | 2021-05-19 | Novartis Ag | Administración sostenida de polipéptidos similares a la angiopoyetina 3 |
| SG11202108832XA (en) * | 2019-02-25 | 2021-09-29 | Pharmabcine Inc | Anti-ang2 antibody and use thereof |
| TW202115112A (zh) * | 2019-06-27 | 2021-04-16 | 德商百靈佳殷格翰國際股份有限公司 | 抗-angpt2抗體 |
| WO2021183849A1 (en) | 2020-03-13 | 2021-09-16 | Genentech, Inc. | Anti-interleukin-33 antibodies and uses thereof |
| AU2021242249A1 (en) | 2020-03-24 | 2022-08-18 | Genentech, Inc. | Tie2-binding agents and methods of use |
| CN115734971A (zh) * | 2020-06-22 | 2023-03-03 | 信达生物制药(苏州)有限公司 | 抗ang-2抗体及其用途 |
| IL302089A (en) | 2020-10-15 | 2023-06-01 | Hoffmann La Roche | Non-covalent protein-hyaluronan conjugates for long-term ocular delivery |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5859205A (en) * | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| US5814464A (en) * | 1994-10-07 | 1998-09-29 | Regeneron Pharma | Nucleic acids encoding TIE-2 ligand-2 |
| US7138370B2 (en) | 2001-10-11 | 2006-11-21 | Amgen Inc. | Specific binding agents of human angiopoietin-2 |
| US7658924B2 (en) | 2001-10-11 | 2010-02-09 | Amgen Inc. | Angiopoietin-2 specific binding agents |
| US7521053B2 (en) * | 2001-10-11 | 2009-04-21 | Amgen Inc. | Angiopoietin-2 specific binding agents |
| RU2277411C1 (ru) * | 2004-12-15 | 2006-06-10 | Ольга Алексеевна Кост | Фармацевтическая композиция для лечения глазных болезней, связанных с нарушением микроциркуляции и/или воспалительными процессами |
| CA2799802A1 (en) * | 2004-12-21 | 2006-06-29 | Astrazeneca Ab | Antibodies directed to angiopoietin-2 and uses thereof |
| KR101017301B1 (ko) | 2004-12-21 | 2011-02-28 | 메드임뮨 리미티드 | 앤지오포이에틴-2에 대한 항체 및 그의 용도 |
| US7956160B2 (en) * | 2005-07-22 | 2011-06-07 | Amgen Inc. | Concentrated protein lyophilates, methods, and uses |
| US20070154482A1 (en) | 2005-09-12 | 2007-07-05 | Beth Israel Deaconess Medical Center | Methods and compositions for the treatment and diagnosis of diseases characterized by vascular leak, hypotension, or a procoagulant state |
| EP3168234A1 (en) | 2005-12-15 | 2017-05-17 | Medimmune Limited | Combination of angiopoietin-2 antagonist and of vegf-a, kdr and/or fltl antagonist for treating cancer |
| AR059066A1 (es) | 2006-01-27 | 2008-03-12 | Amgen Inc | Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf) |
| JP5259423B2 (ja) * | 2006-02-01 | 2013-08-07 | セファロン・オーストラリア・ピーティーワイ・リミテッド | ドメイン抗体構築物 |
| CA2712000A1 (en) * | 2008-01-28 | 2009-08-06 | Medimmune Limited | Stabilized angiopoietin-2 antibodies and uses thereof |
| JO2913B1 (en) | 2008-02-20 | 2015-09-15 | امجين إنك, | Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses |
| US8268314B2 (en) | 2008-10-08 | 2012-09-18 | Hoffmann-La Roche Inc. | Bispecific anti-VEGF/anti-ANG-2 antibodies |
| US8133979B2 (en) | 2008-12-16 | 2012-03-13 | Hoffmann-La Roche Inc. | Antibodies against human angiopoietin 2 |
| US8703132B2 (en) * | 2009-06-18 | 2014-04-22 | Hoffmann-La Roche, Inc. | Bispecific, tetravalent antigen binding proteins |
| JO3182B1 (ar) | 2009-07-29 | 2018-03-08 | Regeneron Pharma | مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2 |
| EP3495387B1 (en) * | 2012-07-13 | 2021-09-01 | Roche Glycart AG | Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases |
-
2009
- 2009-12-11 US US12/635,825 patent/US8133979B2/en active Active
- 2009-12-14 KR KR1020137023369A patent/KR101445518B1/ko active IP Right Grant
- 2009-12-14 WO PCT/EP2009/008930 patent/WO2010069532A1/en active Application Filing
- 2009-12-14 EP EP09793471.5A patent/EP2379592B1/en active Active
- 2009-12-14 SG SG2011044344A patent/SG172216A1/en unknown
- 2009-12-14 PE PE2013002135A patent/PE20140814A1/es active IP Right Grant
- 2009-12-14 CA CA2916481A patent/CA2916481C/en active Active
- 2009-12-14 CN CN201410024638.9A patent/CN103739709B/zh active Active
- 2009-12-14 HU HUE09793471A patent/HUE024545T2/hu unknown
- 2009-12-14 UA UAA201310603A patent/UA105151C2/ru unknown
- 2009-12-14 AU AU2009328613A patent/AU2009328613B2/en not_active Ceased
- 2009-12-14 CA CA2744624A patent/CA2744624C/en not_active Expired - Fee Related
- 2009-12-14 MX MX2011005908A patent/MX2011005908A/es active IP Right Grant
- 2009-12-14 NZ NZ600005A patent/NZ600005A/xx unknown
- 2009-12-14 RU RU2011129204/10A patent/RU2569107C2/ru not_active IP Right Cessation
- 2009-12-14 RU RU2013140625/10A patent/RU2569461C2/ru active
- 2009-12-14 DK DK09793471T patent/DK2379592T3/en active
- 2009-12-14 PE PE2011001109A patent/PE20120551A1/es active IP Right Grant
- 2009-12-14 UA UAA201108713A patent/UA103912C2/ru unknown
- 2009-12-14 KR KR1020117013735A patent/KR101381012B1/ko active IP Right Grant
- 2009-12-14 PT PT97934715T patent/PT2379592E/pt unknown
- 2009-12-14 NZ NZ592856A patent/NZ592856A/en not_active IP Right Cessation
- 2009-12-14 BR BRPI0923434A patent/BRPI0923434A2/pt not_active Application Discontinuation
- 2009-12-14 CN CN201210237207.1A patent/CN102746400B/zh active Active
- 2009-12-14 PL PL09793471T patent/PL2379592T3/pl unknown
- 2009-12-14 ES ES09793471.5T patent/ES2534635T3/es active Active
- 2009-12-14 BR BR122013022089-5A patent/BR122013022089B1/pt active IP Right Grant
- 2009-12-14 JP JP2011539960A patent/JP5559191B2/ja active Active
- 2009-12-14 SI SI200931184T patent/SI2379592T1/sl unknown
- 2009-12-14 MY MYPI2011002743A patent/MY155654A/en unknown
- 2009-12-14 CN CN200980150647XA patent/CN102257008A/zh not_active Withdrawn
- 2009-12-15 TW TW098142952A patent/TWI396549B/zh not_active IP Right Cessation
- 2009-12-15 AR ARP090104876A patent/AR074756A1/es active IP Right Grant
- 2009-12-15 TW TW102107374A patent/TWI482631B/zh active
-
2011
- 2011-05-19 IL IL213039A patent/IL213039A/en active IP Right Grant
- 2011-05-30 ZA ZA2011/03990A patent/ZA201103990B/en unknown
- 2011-05-31 CL CL2011001285A patent/CL2011001285A1/es unknown
- 2011-06-02 MA MA33908A patent/MA32876B1/fr unknown
- 2011-06-09 CR CR20110321A patent/CR20110321A/es unknown
- 2011-06-14 MY MYPI2013003828A patent/MY158438A/en unknown
- 2011-06-16 EC EC2011011139A patent/ECSP11011139A/es unknown
-
2012
- 2012-01-26 US US13/358,813 patent/US8361747B2/en active Active
- 2012-01-26 US US13/358,831 patent/US8399626B2/en active Active
- 2012-07-13 US US13/548,244 patent/US9109027B2/en active Active - Reinstated
- 2012-10-30 CL CL2012003054A patent/CL2012003054A1/es unknown
- 2012-12-04 US US13/693,085 patent/US9340609B2/en active Active
- 2012-12-18 HK HK12113037.4A patent/HK1172349A1/zh unknown
-
2013
- 2013-02-06 US US13/760,118 patent/US9073986B2/en active Active
- 2013-05-13 IL IL226350A patent/IL226350A/en active IP Right Grant
- 2013-08-28 CR CR20130418A patent/CR20130418A/es unknown
- 2013-08-30 JP JP2013179932A patent/JP5814317B2/ja active Active
- 2013-09-09 AR ARP130103201A patent/AR092487A2/es unknown
- 2013-09-30 ZA ZA2013/07297A patent/ZA201307297B/en unknown
- 2013-10-23 PH PH12013502192A patent/PH12013502192A1/en unknown
- 2013-10-25 EC ECSP13011139 patent/ECSP13011139A/es unknown
-
2014
- 2014-07-08 HK HK14106922.4A patent/HK1195775A1/zh unknown
-
2015
- 2015-04-22 HR HRP20150439TT patent/HRP20150439T1/hr unknown
- 2015-05-07 CY CY20151100399T patent/CY1116264T1/el unknown
- 2015-06-04 US US14/731,277 patent/US20150284457A1/en not_active Abandoned
-
2016
- 2016-04-12 US US15/097,097 patent/US20170029493A1/en not_active Abandoned
-
2018
- 2018-02-28 US US15/907,836 patent/US20180282404A1/en not_active Abandoned
-
2019
- 2019-09-26 US US16/583,839 patent/US20200262904A1/en not_active Abandoned
-
2021
- 2021-04-05 US US17/222,776 patent/US20210388071A1/en not_active Abandoned
-
2023
- 2023-03-31 US US18/193,889 patent/US20230227543A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2013140625A (ru) | Антитела против ангиопоэтина-2 человека | |
| RU2012129735A (ru) | Антитела к her3 и их применения | |
| RU2012128651A (ru) | Антитела, связывающиеся преимущественно с внеклеточным доменом 4 человеческого csf-1r, и их применение | |
| EP2471817A3 (en) | Humanized antibody molecules specific for IL-31 | |
| RU2011117410A (ru) | Биспецифические анти-vegf/анти-ang-2 антитела | |
| NZ602892A (en) | Antibodies that bind human cd27 and uses thereof | |
| EA201190132A1 (ru) | Гуманизированные антитела, связывающиеся с cd19, и их применение | |
| RU2011116112A (ru) | Биспецифические анти-egfr/анти-igf-1r антитела | |
| AU2016204274A1 (en) | Antibodies that bind to OX40 and their uses | |
| RU2012142230A (ru) | Антитела против csf-1r человека и их применение | |
| NZ602780A (en) | Human antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof | |
| RU2016100892A (ru) | Антитела против tweakr и их применение | |
| NZ594514A (en) | Interleukin-17 BINDING PROTEINS | |
| RU2012142231A (ru) | Антитела против csf-1r человека и их применение | |
| RU2430111C3 (ru) | Молекулы антител с улучшенными свойствами | |
| EA202091590A1 (ru) | Антитела против pd-l1 и варианты их применения | |
| TW200720289A (en) | Antibodies against CCR5 and uses thereof | |
| RU2014151788A (ru) | Молекула, специфически связывающаяся с rsv | |
| JP2014534239A5 (ru) | ||
| RU2014109039A (ru) | Биспецифические антигенсвязывающие молекулы | |
| WO2005110474A3 (en) | HUMANIZED FcϜRIIB SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF | |
| PE20141398A1 (es) | Anticuerpos neutralizantes de citomegalovirus humano | |
| EA200970879A1 (ru) | Связывающие белки, включающие антитела, производные антител и фрагменты антител, которые специфически связываются с cd154, и их применения | |
| RU2017145268A (ru) | Композиции и способы диагностики и лечения заболеваний, ассоциированных с дегенерацией нейритов | |
| UA109633C2 (uk) | Антитіло людини проти тканинного фактора |